Immunis, Inc. Raises $25 Million to Advance IMM01-STEM in Elderly Patients

  • Immunis, Inc. has secured $25 million in a Series A-1 financing round to fund two Phase 2 clinical trials focused on its novel biologic IMM01-STEM.
  • The financing round included follow-on investments from existing investors and new backing from LifeSpan Vision Ventures, JLS Fund, and a global insurance company.

Immunis, Inc., a clinical-stage biotechnology company focused on developing multi-active biologics for immune-related diseases, has raised $25 million in its Series A-1 financing round. This funding will be used to support two Phase 2 clinical trials for IMM01-STEM, a promising therapy aimed at reversing muscle loss and improving metabolic function in elderly individuals suffering from sarcopenia, obesity, and age-related metabolic dysfunction.

The Series A-1 round was led by existing investors Remiges Ventures, Continuum Health Ventures, and BOLD Capital Partners, with new investments from LifeSpan Vision Ventures, JLS Fund, and a leading global insurance company. The funds will primarily support the next phase of clinical trials, expanding on the promising results from earlier Phase 1/2a studies. These studies demonstrated that IMM01-STEM was safe, with no serious adverse events, and showed improvements in quality of life, physical function, pain management, and gait speed in elderly patients.

“Our Phase 1/2a data in nine elderly patients showed our therapy to be safe with no serious adverse events. Additionally, patients experienced striking improvements in quality-of-life measures related to physical function and pain, as well as a clinically relevant increase in gait speed,” said Mark Cabato, Chief Business Officer of Immunis, Inc. The company aims to continue exploring IMM01-STEM’s potential by conducting randomized, controlled studies in elderly populations with degenerative disease and metabolic dysfunction.

IMM01-STEM’s preclinical trials have already shown substantial promise. Studies in aged mouse models of muscle atrophy and metabolism published in leading journals, including GeroScience and Aging Cell, demonstrated that the therapy could reverse muscle atrophy, improve muscle function, and enhance metabolism. Immunis, Inc. is currently leading the development of the most advanced stem cell-derived biologic in human clinical trials.

“We are grateful for the support of our Board and investors for our mission to maximize health and minimize disease through the development of novel, stem cell-derived therapies,” Cabato added. With this new round of funding, Immunis, Inc. is positioned to make significant strides in addressing unmet medical needs related to age and disease-related immune dysregulation.

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.